Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

JAK2 underexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

JAK2 amplification (2)

JAK2 deletion (1)

JAK2 amplification (2)

JAK2 deletion (1)

›

JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	TL-1-85 Sensitive: C3 – Early Trials TL-1-85 Sensitive : C3	TL-1-85 Sensitive: C3 – Early Trials TL-1-85 Sensitive : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3	QL-VIII-58 Sensitive: C3 – Early Trials QL-VIII-58 Sensitive : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3	fedratinib Resistant: C3 – Early Trials fedratinib Resistant : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3	sunitinib Resistant: C3 – Early Trials sunitinib Resistant : C3